Clinical trials: in Kuwait
Hepatocellular Carcinoma
OREIOS International Study
Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care.
- Trial name
- OREIOS (NCT05239507)
- Where
- 21 sites in Brazil, Egypt and 9 more
- Volunteers
- 1,127 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resectable NSCLC diagnosed between…
- Trial name
- THASSOS-INTL (NCT04808050)
- Where
- 25 sites in Australia, Egypt and 5 more
- Volunteers
- 748 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to…
- Trial name
- CREEK (NCT04964908)
- Where
- 52 sites in Argentina, Brazil and 15 more
- Volunteers
- 1,088 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer.
- Trial name
- HALO (NCT04991051)
- Where
- 24 sites in Kuwait, Oman and 4 more
- Volunteers
- 605 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who are using oral semaglutide and planning to fast during Ramadan.
- Trial name
- O-SEMA-Fast (NCT05716724)
- Testing
- Semaglutide
- Where
- 20 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 288 people
- Sponsor
- Novo Nordisk A/S
Dermatitis Atopic
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment.
- Trial name
- AD-impaCT (NCT05214326)
- Where
- 3 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 187 people
- Sponsor
- Sanofi
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Non-small Cell Lung Cancer
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
This prospective, multicountry, multicentre, non-interventional study plans to include patients who have undergone surgery for early-stage (IA to IIIB on the basis of pathologic criteria) non-squamous NSCLC up to 6 weeks prior to…
- Trial name
- EARLY-EGFR (NCT04742192)
- Where
- 33 sites in Argentina, Chile and 13 more
- Volunteers
- 601 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases.
- Trial name
- PACT-MEA (NCT05317845)
- Testing
- No treatment given
- Where
- 7 sites in Bahrain, Egypt and 5 more
- Volunteers
- 4,089 people
- Sponsor
- Novo Nordisk A/S
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment.
- Trial name
- DISCOVER (NCT02322762)
- Where
- 303 sites in Algeria, Argentina and 30 more
- Volunteers
- 15,992 people
- Sponsor
- AstraZeneca
Diabetes
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c).
- Trial name
- ATOS (NCT03703869)
- Testing
- Insulin glargine (U300)
- Where
- 388 sites in Colombia, Egypt and 16 more
- Volunteers
- 4,589 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Primary Objective: To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).
- Trial name
- LixiRam (NCT02941367)
- Testing
- Lixisenatide (AVE0010), Sulfonylurea, metformin
- Where
- 16 sites in India, Israel and 2 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Relapsing Multiple Sclerosis (RMS)
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without…
- Trial name
- NCT02921035
- Testing
- Rebif (Interferon beta-1a)
- Where
- 41 sites in Algeria, Argentina and 11 more
- Volunteers
- 594 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Covid19
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
This is a prospective, interventional, multi-centre, phase III, randomized, double blind, placebo-controlled, parallel design trial to evaluate the efficacy, safety and tolerability of favipiravir as adjunct ('add on') to…
- Trial name
- NCT04529499
- Testing
- AVIGAN
- Where
- 2 sites in Kuwait
- Volunteers
- 353 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Children and Adolescent With Type 2 Diabetes
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
- Trial name
- NCT01554618
- Testing
- Exenatide Once Weekly
- Where
- 35 sites in United States, Bulgaria and 5 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
- Trial name
- NCT00137020
- Testing
- ziprasidone
- Where
- 27 sites in Egypt, Greece and 7 more
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Hypertension, Hypercholesterolemia
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
- Trial name
- CRUCIAL (NCT00407537)
- Testing
- Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 125 sites in Costa Rica, Croatia and 18 more
- Volunteers
- 1,531 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.